Background: Primary central nervous system lymphomas (PCNSL) are extranodal malignant non-Hodgkin lymphomas (NHL) that arise exclusively in central nervous system (CNS). Diffuse large B-cell lymphoma (DLBCL) is the most common histological subtype. Purpose: To evaluate whether nano drug-loading system-mediated magnetic-targeted thermochemotherapy could produce a better therapeutic effect than single chemotherapy while reducing the use of chemotherapeutic drugs. Magnetic resonance imaging (MRI) was used to monitor tumor progression and H&E staining was used to observe pathological changes of the tumor tissue. Results: In vitro, compared with chemotherapy alone, apoptosis rate of Fe 3 O 4 @MTX mediated thermochemotherapy group was significantly increased, and expression of apoptosis-inducing gene Caspase-3 and Bax were significantly upregulated in OCI-LY18 cells, while expression of apoptosis-inhibiting Bcl-2 gene was significantly downregulated. In vivo, MRI showed successful generation of intracranial tumor, and tumor volume was significantly smaller in combined thermochemotherapy group than in single chemotherapy group. H&E staining result of tumor tissues in each group was consistent with MRI; tumor cells were significantly reduced in thermochemotherapy group. Expression of apoptosis-related gene Caspase-3 and Bax were significantly upregulated in tumor tissues, while expression of Bcl-2 gene was significantly downregulated. Conclusion: These results demonstrated in vivo and in vitro that the combined thermochemotherapy of Fe 3 O 4 @MTX MNPs was superior to the single MTX chemotherapy with less dosage, which may promote apoptosis of DLBCL cells through the mitochondrial apoptotic pathway and provided a new way for the treatment of PCNSL.
Introduction
Primary central nervous system lymphoma (PCNSL) is an extranodal malignant non-Hodgkin lymphomas (NHL) that arise exclusively in the CNS, including the brain, leptomeninges, spinal cord and eyes. [1] [2] [3] Diffuse large B-cell lymphoma (DLBCL) is the most common histological subtype (>90%). 4 It is a rare neoplasm with a median age of 66 years at diagnosis, accounting for 2-3% of all NHL cases but in increasing incidence particularly for elderly patients. 5, 6 So far, the use of high-dose intravenous (IV) methotrexate (MTX) as the backbone regimens, with or without whole-brain radiotherapy and other chemotherapeutics, resulted in significantly improved efficacy, achieving response rates (RR) as high as 70-90%, and median overall survival (OS) of 40-70 months. 7, 8 However, it is now widely recognized that the need for high doses of chemotherapy to achieve valid drug concentrations in cerebral tissues and/or radiotherapy results in a high incidence of delayed neurologic toxicity, occurring in as many as 90% of patients who are older than 60 years. 9, 10 Despite recent therapeutic progress and an apparent improvement in survival figures, outcomes for patients with primary CNS lymphoma remain poor with 20-30% survival at 5 years, clinical research in this field is focused predominantly on the identification of new active agents and combinations to increase efficacy and tolerability of induction chemotherapy.
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In recent times, nanotechnology is extensively offering new approaches to drug delivery, disease diagnose and therapy, especially in cancer research. Functionalization of nanoparticles with cytotoxic drugs has been proven a promising cancer therapeutic method to selectively target tumor cells and reduce systemic toxicity of drugs. 12, 13 One promising cancer therapeutic method is magnetic hyperthermia; tumor cells can effectively be killed by heating to hyperthermic temperatures (42-45°C) during the exposure to an alternating magnetic field (AMF). [13] [14] [15] [16] [17] [18] It involves raising the local temperature of the local malignant tissues which results in an induced cell death without damaging the surrounding healthy tissues, therefore making the cancer cells more sensitive to the effects of certain anti-cancer drugs and minimizing the collateral damage caused by other well-established therapies. 15, 19 Among the nanocarriers that used for drug delivery and cancer therapy, iron oxide nanoparticles (Fe 3 O 4 ) are relatively easy to synthesise, biocompatible, nontoxic, chemically stable and can be superparamagnetic, which have attracted considerable attention for tumor targeting thermochemotherapy. [19] [20] [21] Herein, iron oxide magnetic nanoparticles (IONPs) Fe 3 O 4 as a carrier can move to the tumor location with an external magnetic field after loading the drug, and produce a combined thermochemotherapy effect under magnetic resonance imaging (MRI) monitoring. 18, [22] [23] [24] In our study, the antitumor activity of water-dispersible Pluronic F-127/OA-coated Fe 3 O 4 @MTX nanoparticle formulation was developed in order to lower the use of chemotherapy drug MTX and reduce toxic effects, at the same time achieving better inhibition of PCNSL.
Materials and Methods Materials
The transmission electron microscope was from Hitachi (Japan). The nanoparticle tracking analysis (NTA) and Zeta potentiometer were from Malvern (United Kingdom). UV-VIS -NIR spectrophotometer UV-3600 was from Shimadzu (Japan nanoparticles were determined by TEM (Hitachi, Japan). The NTA (Malvern, UK) was used to detect size distribution, and the magnetic properties of the nanoparticles were analyzed by vibrating sample magnetometry (Quantum Design, USA) at room temperature. Zeta potential was measured using Malvern Instruments (Malvern, UK).
Increasing Temperature Tests
Magnetothermal effects of MNPs were tested in aqueous suspensions (0.5, 1.0, 1.5 mg Fe/mL). The solution was placed in a flat-bottomed test tube on an SPG-06A highfrequency induction heater (f = 230 kHz; I = 30 A; Shenzhen, China) for 60 mins. The temperature was recorded at 5-mins intervals.
Biocompatibility
Cell Culture 3T3 cells were maintained in DMEM medium (Gibco, Thermo Fisher Scientific), mixed with 10% fetal bovine serum (Gibco, Life Technologies) and 1% penicillin-streptomycin (Gibco, Life Technologies) in a standard 5% CO 2 and 37°C incubator.
The cells were passaged every 2-3 days and harvested on exponential growth stage. 
CCK-8 Cytotoxicity Test

Micronucleus Assay of Fe 3 O 4 MNPs
The KM mice were randomly divided into six groups, with five females and five males in each group. The animals were then treated with four concentrations of Fe 3 O 4 MNPs (5.00, 3.75, 2.50 and 1.25 g/kg), 0.9% saline (as negative group) and Cyclophosphamide (CTX) 40 mg/kg (as positive group), respectively. All experimental mice were injected intraperitoneally twice, with a 24-hrs interval, and then sacrificed 6 hrs after the second administration. The thighbone marrows were extracted for smears, fixed 15 mins with methanol, and then washed slides after stained with Giemsa for 15 mins. At least 1000 polychromatic erythrocytes (PEC) were counted for each mouse, and the rate of formation of PEC containing micronucleus (MN) was calculated. SPSS was used to analyze statistic difference between each group.
Acute Toxicity Testing of Fe 3 O 4 @MTX MNPs
The KM mice were randomly assigned into eight groups, with five females and five males in each group. After dissolved in 0.9% saline, Fe 3 O 4 @MTX MNPs were injected intraperitoneally into the mice at dosages of 1.77, 2.51, 3.54, 5.00, 7.06, 9.98, 14.09, and 19.89 g/kg. The general behavior of the mice was observed continuously for 2 hrs immediately after injection and then intermittently observed for a period of 24 hrs. All mice were further observed for up to 14 days after injection, and general physical states, including eating, rest and movement were monitored. Any toxic reaction and death were recorded. Median lethal dose (LD 50 ) was evaluated by SPSS. The animals were euthanized after all of the experiment.
In vitro Evaluation of the Efficacy of Fe 3 O 4 @MTX MNPs on OCI-LY8 PCNSL Cells Cell Culture and Perls Stain
An OCI-LY8 DLBCL cell line was cultured in RPMI1640 medium (Gibco, Thermo Fisher Scientific) supplemented with 10% heat-inactivated fetal bovine serum (Gibco, Life Technologies), 1% penicillin-streptomycin (Gibco, Life Technologies) and incubated at 37°C with humidified air containing 5% CO 2 .
OCI-LY8 cells were seeded into a culture dish (1×10 6 cells) with fresh medium and incubated (37°C, 5% CO 2 ) overnight. The growth medium was then discarded and replaced with fresh medium containing Fe 3 O 4 @MTX MNPs (Fe concentration: 1.0 mg/mL). The cells were incubated (37°C, 5% CO 2 ) for an additional 1 hr; after that, the medium was discarded and cells washed. After fixation by methanol, cells were stained by Perls and observed with an inverted microscope. @MTX MNPs + hyperthermia group as above) were lysed, and the protein concentrations were assessed using BCA assay. Proteins were separated using sodium dodecyl sulfate-polyacrylamide gel electrophoresis and transferred from gel to polyvinylidene difluoride membranes. The membranes were blocked with nonfat milk and after the overnight incubation at 4°C with primary antibodies goat anti-Rabbit IgG (KeyGEN BioTECH, diluted 1:5000), membranes were washed and incubated with secondary antibodies for 2 hrs in dark (Caspase-3 antibody, 1:1000; Bax antibody, 1:1000; Bcl-2 antibody, 1:1000; GAPDH, 1:1000); then, the bands were set into molecular imager and signals were detected.
Flow Cytometry
In vivo Evaluation of the Efficacy of Fe 3 O 4 @MTX MNPs on Intracranial Tumor BALB/c-Nude Mice Model Establishment of Intracranial Tumor Models
Cultured OCI-LY8 cells were washed three times with PBS, counted and kept on ice in DMEM until injection. After anesthetized with 1% pentobarbital, mice were placed in a stereotactic frame. All BALB/c-Nude mice were injected in the right cerebral hemisphere with 5 × 10 5 OCI-LY8 cells (5 μL, 1 μL/min) at 2.0 mm lateral and coordinates 0.5 mm anterior from the bregma and at an intraparenchymal depth of 3 mm. After injection, the needle was left in place for 5 mins after injection. All animal experiments were done following institutional ethics guidelines.
MRI
The life state of the mice was observed daily after the operation, and tumor growth was monitored continuously by MRI after one week. After 12 days, tumor-bearing mice with tumor diameter of 0.5 cm were selected for followed experiments. Successfully modeled BALB/c-Nude mice were divided into six groups (4 mice in each group, half male and half female) as follows: 1) NaCl group (0.02 mL); 2) 
H&E Stain
Brains were removed after perfusion, part of the tumor tissues in each group were fixed, embedded, sectioned and stained with hematoxylin & eosin (H&E) for histopathologic analysis.
qPCR and Western Blot of Tumor Tissues
Part of tumor was then harvested and processed for determination of qPCR and Western blot. The tissues were fully ground in liquid nitrogen, and then the corresponding RNA and protein were extracted after adding the lysate separately. The following processes of quantifying and displaying the strips are as described above.
Statistical Analysis
All statistical analyses were analyzed with SPSS version 19.0 software (SPSS Inc., Chicago, IL, USA); PS, Image J and Origin were commonly used mapping software. Values are shown as mean ± standard deviation (SD). A P-value of 0.05 was considered to be statistically significant. (Figure 1 ). TEM showed Fe 3 O 4 MNPs' core to be approximately spherical in shape and the particles were uniform in size relatively, 16 nm in diameter (Figure 2A ). Whole composite Fe 3 O 4 @MTX MNPs size and size distribution were measured by NTA ( Figure 2B ). It showed that the formulation had an average hydrated diameter of 113 nm with a single peak and a narrow particle size distribution. Moreover, the magnetic properties of Fe 3 O 4 MNPs and Fe 3 O 4 @MTX MNPs were analyzed by VSM at room temperature. Figure 2C shows the hysteresis loops of the samples; there was no hysteresis in the magnetization, with both remanence and coercivity being zero, providing a good demonstration of the superparamagnetic properties. 
Encapsulation and Cumulative Release of MTX
Drug encapsulation efficiency and drug loading efficiency of nanoparticles are crucial properties for their clinical application. The amount of drug loaded was calculated by measuring the amount of MTX remaining in supernatants. Figure 3 and Table 1 reveal the optimal drug encapsulation efficiency and drug loading efficiency. When drug loading efficiency was 15%, drug encapsulation efficiency reached the maximum value of 60.9%, which was selected for the next study. Release of MTX from the complex was also determined by UV-VIS-NIR spectrophotometer, and the cumulative release at various time points was summed ( Figure 4) . The drug release occurred in two phases: an initial burst release, with a significant amount of drug released within 12 hrs; after 12 hrs, the MTX release profiles showed a sustained release pattern and cumulative amount reached 26.3% at 25°C, up to 33.3% at 42°C within 72 hrs. Figure 5A ). Here, we chose 1.0mg Fe/mL as the subsequent therapeutic concentration and compared the heating capacity of Fe 3 O 4 @MTX MNPs of the same iron concentration with ddH 2 O, as shown in Figure 5B .
Increasing Temperature Tests
Biocompatibility Cell Cytotoxicity
The morphological changes of 3T3 cells after treatment with different concentrations of 
MN Results of Fe 3 O 4 MNPs
In our study, the MN formation rates of 5.00, 3.75, 2.50 and 1.25 g/kg experimental groups, negative control group and positive control group were 2.56‰, 2.41‰, 2.29‰, 2.1‰, 2.09‰ and 26.65‰, respectively (Figure 7) , showing a significant difference between the experimental groups and 
Acute Toxicity in Mice Fe 3 O 4 @MTX MNPs
Some behavioral changes such as crouching, apathy and slow response to external stimulus were observed among some animals immediately after Fe 3 O 4 @MTX MNPs injection; most of them resumed normal activity rapidly. The deaths of mice in each group occurred during these 14 days after administration (Table 2) . SPSS were used to calculate the LD 50 of Fe 3 O 4 @MTX MNPs, which evaluated short-term toxicity after intraperitoneal administration. The LD 50 of the complex nano drug-loading system to the mice was 8.579 g/ kg, and its 95% confidence interval (CI) was 6.300-12.333 g/ kg from the acute toxicological study.
In vitro Evaluation of the Efficacy of Fe 3 O 4 @MTX MNPs on OCI-LY8 PCNSL Cells Perls Stain
The stained OCI-LY18 cells were observed under an inverted microscope (10╳100). It was shown that iron reacted with potassium ferrocyanide to form iron ferrocyanide precipitated in the intracellular iron, which manifested that Fe 3 O 4 @MTX complex MNPs could enter OCI-LY18 cells easily (Figure 8 ).
Apoptosis Assay
The rate of apoptotic OCI-LY18 cells after 48 hrs of treatment is shown in Figure 9 . It showed that the main function of our therapy was to induce apoptosis of OCI-LY18 cells in vitro. Notes: n = 3, mean ± standard deviation. MRI was performed 12 days after tumor implantation, and the results showed that the modeling was successful, and the mice with tumor in diameter about 0.5 cm was selected for treatment. After administration, MRI showed a low-signal region where MNPs accumulated in tumor location after a strong magnet was placed on the right side of the mice brain ( Figure 11A ). As Figure 11B Brain tissues of each group were taken and fixed by formalin immediately after perfusion, and the results were observed after H&E staining (Figure 12 ). The number of tumor cells in the combined thermochemotherapy Fe 3 O 4 @MTX MNPs group was significantly reduced compared with the single chemotherapy group and replaced by cell interstitial, which was consistent with the imaging results. Figure 13A ). The protein expressions of Caspase-3, Bax and Bcl-2 in tumor tissues were examined by Western blot as shown in Figure 13B . Semi-quantitative results were basically consistent with qPCR results ( Figure 13C ). 
qPCR and Western Blot of Tumor Tissues
Discussion
Combination therapy is the most promising treatment method, aiming to improve efficacy and reduce the dosage of single drug. The application of traditional treatments for tumors has gradually shown many limitations. Magnetic fluid hyperthermia as a special physical way, which could increase the temperature above 42°C and targeted to various tumor cells and tissues, has gained more and more attention and recognition. [40] [41] [42] [43] In our study, we have developed water-dispersible superparamagnetic MTX loaded Pluronic F-127/OA-coated Fe 3 O 4 MNPs, which had an average hydrated diameter of 113 nm ( Figure 2B ). Superparamagnetic properties of MNPs in various research were proven well after coated with kinds of materials, 25, 44 Figure 2C shows that remanence and coercivity Figure 5 . Biocompatibility of our Fe 3 O 4 MNPs carrier was tested in 3T3 cells and KM mice and results showed less cell cytotoxicity and no genotoxic (Figures 6 and 7) . The results of Figure 11A shows MNPs could target tumor tissues under the guidance of external magnetic field; High signal regions indicated by the arrows in Figure 11B show tumors after various treatments; * P<0.05. Abbreviation: MNPs, magnetic nanoparticles.
acute toxicity test showed that LD 50 of Fe 3 O 4 @MTX MNPs drug-loading system was 8.579 g/kg (Table 2) ; moreover, the safety range (95% CI: 6.300-12.333 g/kg) was wider than Fe 3 O 4 @Au composite MNPs (95% CI: 6.58-10.72 g/kg). 25 In vitro, the cell apoptosis was measured by flow cytometry (Figure 9 ), and then qPCR and Western blot were performed to evaluate the molecular mechanisms of inducing apoptosis in OCI-LY18 cells and mice tissues (Figures 10 and 13 ). Tamas Vancsik et al indicated that hyperthermia could significantly reduce antiapoptotic XIAP, BCL-2 and BCL-XL and elevated proapoptotic BAX and PUMA, may further raise the sensitivity and/or reduce the therapeutic concentration and side effects of Dox. 26 The results of Mantso et al showed that hyperthermia can exert therapeutic effectiveness against melanoma and colon carcinoma by inhibiting a number of critical cellular cascades including apoptosis, proliferation and DNA damage. 46 The combined thermohyperthermia mediated by Fe 3 O 4 @MTX MNPs in our study exhibited superior therapeutic efficacy on OCI-LY18 PNCSL cells by synergistic effects between chemotherapy and apoptosis, transcription and translation of apoptosis-inducing gene Caspase-3; Bax were significantly upregulated while apoptosis-inhibiting gene Bcl-2 were significantly inhibited in combined hyperthermia groups, indicating its excellent antitumor effect by inducing intrinsic apoptosis. After successful construction of mice intracranial tumor models, in vitro results indicated that hyperthermia can help inhibit tumor cells and thermochemotherapy of Fe 3 O 4 @MTX +H group achieved significant therapeutic effects compared with other groups. Both MRI and pathology supported this conclusion (Figures 11 and 12) . Furthermore, MRI in vivo show that the intensity and signal change rate of tumor tissues were decreased after tail vein injection of Fe 3 O 4 @Au-C225 composite targeted MNPs indicated by Ge et al. 47 Our findings are similar with Ali Shakeri-Zadeh et al 48 which states that MNPs could be guided by an external magnetic field and immobilized in the tumor as observed by the dark regions. Recently, some study indicated folateconjugated gold nanoparticles could increase the efficiency of cancer diagnosis and therapy, which inspires us to improve our modification on Fe 3 O 4 nanoparticles to get better targeting. 
Conclusion
In summary, we have successfully constructed and characterized Fe 3 O 4 @MTX nano drug-loading system which could combine efficiently magnetic targeting, magnetic hyperthermia and chemotherapy into a whole. In addition, the combined effect could significantly improve the treatment effect, while reducing the use of chemotherapy drugs to avoid side effects. Finally, we conducted a preliminary exploration of the feasibility and possible mechanisms of inducing tumor apoptosis. In addition, we have performed proteomics to detect new possible proteins and acetylation sites in the MTX single chemotherapy group and Fe 3 O 4 @MTX+H thermochemotherapy group, and further optimize the hyperthermia conditions to explore whether the combined hyperthermia could stably inhibit the MTX key enzyme dihydrofolate reductase (DHRF) to solve the drug tolerance problems. 
